Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia

OBJECTIVE: Oral tyrosine kinase inhibitors (TKIs) are first line therapy for chronic myeloid leukemia (CML). A complete cytogenetic response (CCyR) correlates with increased overall survival, however only 66%–88% of patients achieve CCyR after one year of TKI treatment. Because TKI therapy alone can...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokorny, Rebecca, Stenehjem, David D., Gilreath, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Practice Issues
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047107/
https://www.ncbi.nlm.nih.gov/pubmed/35132891
http://dx.doi.org/10.1177/10781552221077254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047107/
https://www.ncbi.nlm.nih.gov/pubmed/35132891
http://dx.doi.org/10.1177/10781552221077254

Ejemplares similares